G
Guangzhou Xinji Pharmaceutical Technology
Pharmaceutical company specialising in innovative drug preparations and research
About Guangzhou Xinji Pharmaceutical Technology
Guangzhou Xinji Pharmaceutical Technology Co., Ltd., operating under the name Novaken, was established in 2007 as a specialized pharmaceutical contract research organization (CRO). The company was founded by Dr. Wu Chuanbin, who serves as the Chief Scientist. Dr. Wu possesses an extensive background in pharmaceutics, holding a Ph.D. from the University of Texas at Austin and having occupied senior research and development roles at major international pharmaceutical firms such as Johnson & Johnson, Novartis, and Actavis. His industrial experience is complemented by a distinguished academic career, including being the first Chinese scientist named a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and serving as a committee member for the National Pharmacopoeia.
The firm's business model is twofold, encompassing both contract research services and proprietary product development. The Pharmaceutical Contract Research Organization (PCRO) arm delivers a comprehensive suite of services to other pharmaceutical companies, including pre-formulation studies, process development, quality research, and regulatory support for FDA and EU submissions. This division aids clients in areas like generic drug consistency evaluation and new drug Chemistry, Manufacturing, and Controls (CMC) research. Novaken has established collaborations with numerous well-known domestic pharmaceutical enterprises, such as Zhuhai United Laboratories, Guangzhou Baiyunshan Pharmaceutical, and CR Sanjiu.
Concurrently, the company pursues a Pharmaceutical Product and Process Research & a-lOut-licensing (PPRO) model, focusing on the development and subsequent licensing of high-barrier formulation products. Central to this strategy are several core technology platforms, including sustained and controlled-release formulations, solubilization of poorly soluble drugs, and inhalation drug delivery systems. A key area of expertise is its microneedle technology for transdermal drug delivery. The company has developed a proprietary automated production system for creating soluble microneedle chips, which can deliver peptides, proteins, vaccines, and small molecules through the skin, aiming to improve patient compliance by offering a painless alternative to injections. This technology has applications in both pharmaceuticals and medical aesthetics. Recent milestones include receiving clinical trial approval in 2024 for a dexmedetomidine microneedle patch for pediatric sedation and a nasal spray for Parkinson's disease, with commercial launch anticipated for both around 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Feb 2025 | $14M | $55M | Jinke Entertainment Culture · Gree Electric Appliance · Gree Gold Investment | ↗ |
| DEBT✓Debt | Dec 2021 | $14M | — | Danlu Capital | ↗ |
Growth signals
Latest recorded traffic for Guangzhou Xinji Pharmaceutical Technology is 530 monthly website visits, up 17.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guangzhou Xinji Pharmaceutical Technology in the Guangzhou ecosystem
The Guangzhou Xinji Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
- DCDanlu Capital
Jinke Entertainment Culture- GAGree Electric Appliance
Gree Gold Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Xinji Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Xinji Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









